The State University of New York

Kdx Diagnostics, Inc.

Kenneth R Shroyer

Luisa F Escobar-Hoyos

Nam Hoon Kim

The current disclosure provides methods for detecting and analyzing K17 expression in a bladder sample obtained from a subject. The current disclosure also pertains to methods and kits for identifying a mammalian subject with bladder cancer by detecting the expression of K17 in a sample. The present methods include both cell-based and cell-free methods for determining the level of keratin 17 in a sample obtained from the bladder of a subject.

Keratin 17 as a biomarker for bladder cancer

The instant application relates to methods for determining pancreatic cancer patient outcome and directing treatment to subjects with pancreatic cancer. The present disclosure further provides methods for measuring expression levels of cytokeratin 17 in a subject having pancreatic cancer, such as pancreatic ductal adenocarcinoma, in order to determine the subject's survival rate and clinical outcome.

Growing community of inventors

Setauket, NY, United States of America

Kenneth R Shroyer